Key developments that have caused AMD stock to decline recently: 1️⃣ $INTC, SoftBank, and $ARM Collaboration Rumors: $Softbank's $2 billion investment in $INTC, and rumors that this partnership could leverage $INTC's foundry facilities for the production of AI chips using the $ARM architecture, have raised concerns about further intensified competition for $AMD. This is seen as a risk to market share. 2️⃣ Order Cut and Analyst Note: Hong Kong GF Securities analyst Jeff Pu's claim that $AMD reduced its MI355X chip orders from $7 billion to $6 billion has weakened the company's growth prospects in the AI chip segment. This news has shaken investor confidence and put pressure on the stock. ​3️⃣ New Licensing Requirements for Sales to China: The US government's requirement that NVDA and AMD apply for licenses for every new-generation chip sale to China could restrict companies' flexibility and revenue streams in the Chinese market. This development makes sales processes more complex. Furthermore, according to some agreements, companies are required to pay 15% of revenue from sales to China to the US government. ​4️⃣ Possible US Government Partnership in $INTC: The US's announcement of its intention to become a partner in $INTC is perceived as a potential risk that could alter the competitive landscape. This could mean supporting $INTC with special taxes imposed on companies like NVDA and AMD, which could increase AMD's costs and negatively impact its competitiveness. #AMD #Stock #Investment #TechNews #Market #INTC #NVDA #SoftBank #ARM #ChipSector

I love how Cardano is creating a pathway to bring in Bitcoin users. This ties in perfectly with Titans and Banker Labs who are creating a pathway to earn rewards for their investors through Bitcoin mining.

The issue that frightens investors in the US markets and is constantly being talked about by those who know the old hat: Shortness of Breath Because the majority of the stock market returns still come from a few giant companies. While the rally has broadened somewhat, a few stocks still dominate the market. The top 10 companies (Nvidia, Microsoft, Apple, Amazon, Alphabet, Meta, Broadcom, Tesla, Berkshire Hathaway, and JPMorgan Chase) account for the following percentages: - 40% of the total value of the S&P 500 - 56% of the increase since the bottom on April 8 - 31% of the revenue growth over the last 12 months - 55% of the net profit growth over the last 12 months - 69% of the capital expenditure growth over the last 12 months What do these figures tell us? These companies (perhaps with the exception of Tesla) deserve high valuations because both their revenue and profitability are growing much faster than other companies. So, are these companies expensive? As you know, those who memorize this topic love to reference the .com bubble of 2000. But today's situation is very different. During the .com bubble, Cisco traded at 85x forward P/E, and Oracle at 90x. Today, Alphabet is at 20x, and Broadcom at 43x. Furthermore, most of the 2000 crash occurred in unprofitable, smaller technology companies. Admittedly, today's top 10 companies aren't particularly cheap either. But they're nowhere near the valuations they were during the .com crisis (with the exception of Tesla). Could these companies' valuations be adjusted? Of course. But comparisons to the 2000 bubble and fears of market recession aren't very meaningful.

📉📈 📰🗞️ https://www.cointribune.com/en/cardano-futures-volume-explodes-and-inspires-crypto-investors/?utm_source=coingecko&utm_content=coingecko&utm_campaign=coingecko&utm_medium=coingecko&utm_term=coingecko

$KULR KULR Technology Balance Sheet Summary; 💰 Financial Results - Revenue increased by 63% year-over-year to $3.97 million, the highest level in the company's history. - Net income was $8.14 million ($0.22 per share); a loss of $5.89 million was reported in the same period last year. - Product sales increased by 74% to $1.98 million. - Gross margin decreased to 18% (24% in the previous year), due to unexpected labor costs. - SG&A expenses increased by 51% to $6.94 million, and R&D expenses increased by 86% to $2.44 million. - Operating loss increased to $9.45 million. ₿ Bitcoin Strategy - The company holds 1,035 BTC, worth approximately $101 million. - BTC yield was reported as 291.2%. - A $20 million loan agreement was signed with Coinbase; it will be used for Bitcoin purchases. ⚙️ Operational Developments - Bitcoin mining capacity reached 750 PH/s; target 1.25 EH/s. - The K1S 500 XLT energy storage solution was delivered to customers for the space sector. - The K1G battery successfully passed ballistic resistance tests. - The pressure-resistant submarine battery was delivered to a strategic partner. 🤖 New Technologies and Partnerships - A partnership was established with German Bionic; the 7th generation EXIA exoskeleton was introduced in North America. - Included in the Russell 3000 Index; institutional investor interest may increase. - An 8-for-1 reverse stock split was completed; as part of a market positioning strategy.

📊 MAG7 vs. S&P 493 – April 7 → August 12, 2025 The market picture is clear: The big ones are carrying, the broad base is providing limited support. Here's an X-ray of the last 4.5 months ⬇️ 🔹 MAG7 (AAPL, AMZN, GOOGL, META, MSFT, NVDA, TSLA) • Index Weight: ~35.4% 📈 (record high) • Performance: +10.7% • Earnings growth +28% in Q1, continued strong in Q2 • Still priced in with the "AI + quality growth" narrative • Risk: High valuation → susceptibility to surprises 🔹 S&P 493 (Remainder) • Performance: +4.1% (RSP index) • Breadth: 55% at 200-day moving average • Earnings growth, but above-index momentum is limited • Valuation is more reasonable → potential for "catch-up" 🔹 Overall Index (S&P 500) • Performance: +8.3% • P/E: 22.1x → Above 5- and 10-year moving averages • Q2 earnings growth: 11.8% (mega-caps again the driving force) 📌 Reading: While the MAG7 rebounded ~35% from its April 7 lows, the broad base remains moderate. Most of the index's rise comes from giants. Concentration risk is high → the impact is disproportionate, both in the uptrend and downtrend. 📌 Tactical Recommendation: - Strengthen the Majors: Include companies with growing profits and strong balance sheets (excess cash) within the MAG7 in your main portfolio. - Layer the Rest: Add small-medium weightings to sectors (healthcare, select industrials, some defensive stocks) within the 493 whose earnings expectations have been revised upwards and whose prices remain reasonable. - Divide Risk: Don't concentrate your investment solely on giant stocks; Diversify with products like the equal-weight index (RSP) or the S&P 500 – Excluding Top 10 Stocks. - Follow the Macro: Fed interest rate decisions, inflation data, and global trade news can quickly change the direction of mega-cap stocks in particular. This is not investment advice, but for informational purposes only!!! #MAG7 #SP500 #Finance #StockMarket #Investment #Stocks #MarketAnalysis #Investor #BorsaIstanbul #NASDAQ #WallStreet #Economy #FinancialLiteracy #Index #InvestmentStrategy #Portfolio

As the rally in technology stocks boosts market sentiment, investors continue to assess the impact of Trump's new tariffs. 🔹 S&P 500 futures: +0.3% 🔹 Nasdaq 100 futures: +0.3% 🔹 Dow futures: +0.2% 📊 Bond Market 10Y return: 4.26% (flat) 2Y return: +1bp ➡ 3.75% 📌 Thursday Summary S&P 500: -0.08% (Eli Lilly earnings pressured) Nasdaq: +0.35% 🆙 Mag-7: +0.40% 📈 (All-time high) 💬 Deutsche Bank – Jim Reid: “Trump’s chip tax exemptions and the easing of Russia-Ukraine tensions have tempered optimism. Tariffs have taken effect, but the market reaction has been weak.” 📰 Other Developments Trump tariffs officially began last night Fed Governor Waller is emerging as a candidate for chairman after Powell Today's data agenda is quiet; St. Louis Fed President Musalem will speak #SP500 #Nasdaq #DowJones #TrumpTariffs #BondMarket #Fed #Markets

$HIMS Hims & Hers' Weight Loss Strategy Shakes Up Balance Sheet Metrics! 📉 Telehealth platform Hims & Hers surprised investors by missing Wall Street expectations for the first time, despite a 73% year-over-year increase in revenue to $544.8 million in the second quarter. This led to a 13% post-session drop in the stock. The primary reason behind this unexpected decline in figures is forced changes to the company's GLP-1 (weight loss) drug strategy. With the FDA's end of the semaglutide shortage, Hims was forced to change its sales model for more affordable generic GLP-1 drugs. This led to a decline in online GLP-1 revenue from $230 million in the first quarter to $190 million in the second quarter, and a decrease in average revenue per subscriber from $84 to $74. While the company achieved 31% year-over-year subscriber growth, reaching 2.4 million subscribers, uncertainties surrounding its GLP-1 strategy and developments such as the termination of its partnership with Novo Nordisk cast doubt on its growth narrative. Negative free cash flow is another concern. Hims & Hers will now attempt to navigate this challenging period by focusing on personalized GLP-1 therapies.

📊 $LLY | Eli Lilly Q2'25 Financial Results Strong Growth, Deepening Pipeline 🔹 Revenue: $15.56B (+38% YoY) 🟢 🔹 Adjusted EPS: $6.31 (+61% YoY) 🟢 🔹 Zepbound: $3.38B (+172%) 🔹 Mounjaro: $5.20B (+68%) 💡 Zepbound and Mounjaro solidify Eli Lilly's leadership in the metabolic diseases segment, with this quarter's results demonstrating momentum for both prescription penetration and patient acceptance of these products. 📌 FY25 guidance revised upward: ▫️ Revenue: $60–62B ▫️ Adj. EPS: $21.75–$23.00 🔬 Positive developments in the pipeline (Orforglipron, Jaypirca, Kisunla) present very strong catalysts that will support growth in the medium to long term. 💼 It also appears to be continuing its focus on innovation with the acquisitions of SiteOne and Verve Therapeutics and the Purdue collaboration. 📈 Comment: Eli Lilly is demonstrating not only strong sales growth but also a structural transformation. Supported by its leadership in the GLP-1 class, cardiometabolic protection data, and R&D investments, the pipeline offers a defensive and growth combination for long-term investors. #LLY #EliLilly #Balance Sheet #GLP1 #Zepbound #Mounjaro #HealthcareSector #StockAnalysis

🧠 $BMNR | The art of Ethereum accumulation, or a strategy lesson? 🔹 July 29: 625K $ETH purchased, avg: $3,755 🔹 August 4: Position increased to 833K ETH, avg cost $3,492 🔹 Was the new 208K ETH purchased at an average price of $2,702? ❗️Yet, spot ETH never fell below $3,380 during this period. ➡️So how did BMNR buy at such a low price? Answer: Could be forward agreements or structured derivatives contracts. ETH was around $2,500 during the "big bang" announcement at the end of June. Call rights were likely created at that time and are now being activated. This may be the reason for the recent surge in the stock: Investors are waking up to this strategic buying. If ETH additions continue at this rate, BMNR will be one of the few companies collecting below the spot price. Tommy L and his team may be making a very smart play. #ETH #Ethereum #BMNR #CryptoStocks #Blockchain #InvestmentStrategy #SmartMoney

📉 Unfortunately, a lackluster earnings report for AMD. I was afraid of weak EPS, and it came true. At least there are positive signals on the forward guidance side. However, when expectations are set high, high price volatility is inevitable. If we hold above $170, perhaps even close the week above this level, we will have survived with minimal damage. The market loves to exaggerate. Conversely, if a correction is possible, a dip to $140-$150 could be a buying opportunity for those looking to add to their portfolio. 📢 Here are my key points: • Q3 guidance does not include the MI308 revenues planned for sale to China. The sale is still awaiting approval. However, there is a large amount of equipment in stock, ready for immediate shipment. • We still haven't seen the expected AI boom. Lisa Su points to the MI350 ramp-up for this. The market and investors now want to see results. The second half of 2025 is critical.

Some of the strongest cardano cnts plays imho (not financial advice) are $IAG - decentralized digital storage and compute making amazing headway with Fortune 50 companies. $FLDT. FluidTokens is not just a lending platform but also working to bring Bitcoin to cardano. $TITAN - an aggregator of various decentralized physical infrastructures networks (DePin) and mining investor that brings value to holders. $BANK which brings DeFi and mining shares to holders. And there are a few others I'd like to expand to but can't at the moment like $AGIX which is a promising AI venture. $GENS has been slower to develop than I'd like but it could end up being a strong choice for Bitcoin DeFi and RWAs. Always do your own research. Diversification is key without becoming spread too thin. What is the utility of the project? Is the team visibly building and what value do they bring to holders? Have your key holdings that you continually stack and set yourself some targets.